<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256372</url>
  </required_header>
  <id_info>
    <org_study_id>AP214-CS007</org_study_id>
    <nct_id>NCT01256372</nct_id>
  </id_info>
  <brief_title>An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery</brief_title>
  <official_title>An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Action Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Action Pharma A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effect of two dose-levels of AP214 on the prevention of (acute)
      kidney injury after cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>90 days</time_frame>
    <description>To assess the safety and tolerability of AP214 compared to placebo; by analysis of number and nature of Adverse Events (AEs), Serious Adverse Events (SAEs), changes in laboratory parameters and overall health status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the effect of AP214 versus placebo on the maximal postoperative change in absolute values of Serum Creatinine (SCr) compared to baseline within the first 7 days after surgery or until discharge from hospital, whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>90 days</time_frame>
    <description>To assess the ability of AP214 compared to placebo to reduce postoperative changes in SCr, and eGFR at day 28, 60 and Day 90 and GFR at Day 90 compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Coronary Artery Bypass</condition>
  <condition>Aortic Aneurysm</condition>
  <condition>Valve Surgery</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>AP214; dose-level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP214; dose-level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AP214; dose-level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP214; dose-level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to AP214</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP214</intervention_name>
    <description>AP214</description>
    <arm_group_label>AP214; dose-level 1</arm_group_label>
    <arm_group_label>AP214; dose-level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo; intravenous infusion</description>
    <arm_group_label>Placebo to AP214</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has signed the trial-specific informed consent form.

          2. Patients ≥ 18 years old, male or female, not of childbearing potential (postmenopausal
             or permanently sterilized, e.g. tubal ligation, hysterectomy, bilateral
             salpingectomy), regardless of ethnicity.

          3. Patients undergoing combined coronary artery bypass grafting (CABG) surgery and
             surgery of one or more cardiac valve (valve(s) surgery), or

          4. Patients undergoing surgery of more than one cardiac valve (valves surgery), or

          5. Patients undergoing surgery of the aortic root or ascending part of the aorta, or

          6. Patients undergoing surgery of the aortic root or ascending part of the aorta,
             combined with CABG and/or valve(s) surgery, or

          7. Patients with stage III chronic kidney disease (eGFR 30-59 ml/min determined by the
             Modification of Diet in Renal Disease (MDRD formula)) undergoing CABG or Valve surgery

        Exclusion Criteria:

          1. Cardiac surgery to be performed &quot;off pump&quot; without cardiopulmonary bypass.

          2. Cardiac surgery to be performed with hypothermic circulatory arrest.

          3. Confirmed or suspected endocarditis.

          4. EF ≤ 20%, evaluated within 2 months prior to screening visit.

          5. Requiring a reoperation on one of the valves within 3 months following the original
             valve surgical procedure.

          6. Active peptic ulcer disease and gastritis.

          7. Receiving dopamine, adrenalin or noradrenalin at any dose at any time 14 days prior to
             Day of surgery.

          8. Known or suspected hypersensitivity to the investigational medicinal product.

          9. Current participation in any other interventional clinical trial.

         10. Previously dosed with AP214.

         11. Use of investigational medicinal products within the previous 6 months.

         12. Body weight above 130 kg.

         13. History of any organ transplant.

         14. Women who are of childbearing potential, pregnant, or breast-feeding.

         15. Current abuse of alcohol or substance, according to the investigator's medical
             judgment.

         16. Has a mental incapacity or language barriers precluding adequate understanding of
             trial procedures.

         17. Any history of cancer within the last 2 years

         18. Any history of dialysis.

         19. Is considered by the Investigator unsuitable to participate in the trial for any other
             reason, for instance due to a significant serious underlying condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Action Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Action Pharma A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Copenhagen, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac surgery</keyword>
  <keyword>Acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

